United States Drug Patent 12,295,925: Scope, Claim-by-Claim Coverage, and Practical Patent Landscape for Pediatric NF1 Inoperable Plexiform Neurofibromas
Executive scope: US Patent 12,295,925 claims methods for treating pediatric patients (ages 2 to 15) with NF1-associated inoperable plexiform neurofibromas (PN) using orally administered mirdametinib. The strongest claim anchor is treatment-execution constraints: (i) no prior MEK inhibitor exposure, (ii) mirdametinib dosing regimens by BSA and/or maximum daily dose, (iii) intermittent 3-weeks-on/1-week-off administration, and (iv) objective volumetric response thresholds defined by centrally read MRI analysis. The remaining claims add clinical selection criteria (NIH NF1 diagnostic rules, confirmed constitutional NF1 mutations), lesion-characterization subtypes (head/neck, airway/great vessels, plexus, paraspinal, deformity/disfigurement, painful lesions), and measurable outcomes (volume reduction, pain intensity, pain interference).
What does US 12,295,925 actually cover?
Who is covered?
Claim scope is limited to pediatric human patients aged 2 to 15 with:
- NF1-associated inoperable plexiform neurofibromas (PN).
- A treatment naïve status: “no prior exposure to MEK inhibitors.” (Claims 1, 14, 15)
What is the covered drug and route?
- mirdametinib is administered orally. (Claims 1, 14, 15)
- A specific oral dosage form construction is claimed for at least one embodiment:
- disintegrating/dissolving dispersible tablet containing 1 mg mirdametinib in a potable liquid to form a solution (Claim 23).
What is excluded?
- Any patient with prior MEK inhibitor exposure is outside claim coverage as written.
- Any adult patient (outside 2 to 15 years) is outside the method claims.
Claim structure and scope: independent claims vs layered dependent claims
Independent claims: what are the hard boundaries?
US 12,295,925 as provided includes the following method claim bases:
-
Claim 1 (core independent):
Oral mirdametinib to a 2 to 15 pediatric NF1 patient with inoperable PN and no prior MEK inhibitor exposure.
-
Claim 14 (independent):
Same population and core conditions, with maximum daily dose limited to 4 mg twice daily (note: as written, the claim states “maximum daily dose is 4 mg mirdametinib twice daily,” which is internally definitional of a per-dose cap rather than a daily cap; operationally, it locks the regimen ceiling).
-
Claim 15 (independent):
Same population and conditions, with a 3-weeks-on/1-week-off schedule:
- administered for the first three weeks of each four-week period
- discontinued for the last one week.
-
Claim 23 (independent as provided):
Same population and conditions, with a specific dosage form procedure:
- twice daily (i) dispersible tablet 1 mg in potable liquid, (ii) administer resulting solution.
Dependent claims: what refinements narrow infringement?
Claims 2-13, 16-22, 24-25 narrow or operationalize the method by adding:
- clinical severity and lesion type (Claims 2, 3, 4, 5, 6-8)
- functional status requirement (Claim 9)
- NIH diagnostic rule detail and molecular confirmation (Claims 10, 11, 12)
- BSA titration regimen (Claim 13)
- measured outcomes tied to imaging and patient-reported measures (Claims 16-18)
- adverse event-driven dose reduction algorithm and specifically acneiform AE (Claims 19-20)
- objective response-based selection and specific response-rate thresholds (Claims 21-22)
- osseous lesion specifics inside established NF1 diagnostic categories (Claims 24-25)
Claim-by-claim coverage map (with business-usable infringement levers)
Claim 1: core method claim
Text essence:
A method of treating pediatric NF1 with inoperable PN via oral mirdametinib where the patient has no prior MEK inhibitor exposure.
Practical scope levers:
- If clinical trials or commercial use treats treatment-naïve MEK status, this claim is the first line of coverage.
- If a competitor uses mirdametinib in a patient previously treated with a MEK inhibitor, claim 1 and all claims depending on the same premise (as written) are structurally harder to meet.
Claims 2-5: symptomatic, progressing, morbidity-based disease state
- Claim 2: symptomatic, inoperable PN
- Claim 3: progressing or causing significant morbidity
- Claim 4: progressive PN
- Claim 5: tumors causing significant morbidity (note spelling “moribidity” in claim text)
Infringement risk driver:
A method is easier to argue when use is limited to patients meeting progression/morbidity or symptom criteria in labeling, protocol, or marketing.
Claim 6-8: lesion anatomic and severity subclasses
- Claim 6: includes multiple lesion categories:
- head and neck lesions compromising airway or great vessels
- brachial or lumbar plexus lesions causing nerve compression and loss of function
- lesions causing major deformity or significantly disfiguring lesions
- extremity lesions causing limb hypertrophy or loss of function
- painful lesions
- Claim 7: deformity/disfigurement must be tumors unable to be concealed by standard garments (head and neck or other areas)
- Claim 8: paraspinal lesions
Business-usable differentiation:
If a competitor runs studies or positions a regimen around different lesion patterns (or excludes certain severe anatomic sites), it can attempt to stay outside these dependent claims while still potentially falling under Claim 1.
Claim 9: functional status
- Lansky performance at least 60%.
Infringement risk driver:
This becomes a narrow criterion for labeling-concordant use. Use in patients below 60% could reduce exposure to claims 9 and any dependent pathway.
Claim 10-12: NF1 diagnostic confirmation granularity
- Claim 10: NF1 diagnosis using NIH Consensus Conference plus at least one specific criterion set:
- café-au-lait macules threshold by pre- vs post-pubertal size
- freckling location
- optic glioma
- Lisch nodules
- distinctive bony lesion
- first-degree relative
- Claim 11: constitutional NF1 mutation documented in a CLIA/CAP certified lab
- Claim 12: diagnosis logic includes parent-based criterion or non-parent-based criterion set requiring two or more items, including:
- expanded café-au-lait thresholds
- freckling
- neurofibroma/plexiform presence
- optic pathway glioma
- Lisch/choroidal abnormalities
- osseous lesion
- heterozygous pathogenic NF1 variant with VAF 50% in normal tissue
Coverage insight:
Claims 10-12 do not change the drug but change the eligibility definition, which matters for infringement when protocols define diagnosis criteria for enrollment and use.
Claim 13: BSA-based initial dosing algorithm
Initial dosing by body surface area (BSA), twice daily:
- ≤ 0.69 m²: 1 mg BID
- 0.7 to 1.04 m²: 2 mg BID
- 1.05 to 1.49 m²: 3 mg BID
- ≥ 1.5 m²: 4 mg BID
Operationally important:
This is a clean regimen table that can be mapped to prescribing patterns, trial dosing rules, and label dosing instructions.
Claim 14: maximum dose framing
- Same core method conditions, with “maximum daily dose is 4 mg mirdametinib twice daily.”
Practical effect:
It sets a ceiling consistent with the BSA table max dose (4 mg BID) and reduces argument room for any supra-max dosing approach.
Claim 15: 3-weeks-on/1-week-off schedule
- Each four-week period: first three weeks dosing, last week discontinued.
Regulatory and commercial impact:
Any regimen that is continuous (or has a different cycle length) is less likely to map to this dependent claim.
Claim 16: imaging outcome threshold
- At least 20% reduction in PN volume by volumetric MRI analysis after treatment.
Key infringement driver:
If a product claims or measures response by a different imaging metric (or uses different threshold), this claim may be harder to satisfy.
Claims 17-18: pain-related endpoints
- Claim 17: decreased pain intensity
- Claim 18: decreased pain interference
Practical scope:
These introduce patient-reported outcome endpoints; infringement depends on how treatment benefit is evidenced or how endpoints are framed in method use.
Claims 19-20: dose reduction algorithm by AE, with acneiform specified
Claim 19: dose reduction based on event timing dose:
- If at time of event: 1 mg BID → reduced daily dose: 1 mg morning only
- If 2 mg BID → reduced daily dose: 2 mg morning + 1 mg afternoon/evening
- If 3 mg BID → reduced daily dose: 2 mg BID
- If 4 mg BID → reduced daily dose: 3 mg BID
Claim 20: AE that triggers reduction is specifically acneiform.
High-value lever for landscape:
A competitor can attempt to avoid this dependent claim if its clinical protocol uses different AE trigger logic and dose adjustment rules, even if it still prescribes mirdametinib.
Claims 21-22: selection based on objective response rate threshold
- Claim 21: selecting mirdametinib based at least on objective response rate defined as:
- at least 20% decrease in tumor size
- using centrally read MRI volumetric analysis
- Claim 22: selection based on response rate of at least 70%
Interpretive impact:
These claims look like clinical decision support logic with explicit response thresholds.
Claim 23: dispersible tablet dosing to form a solution
- twice daily oral administration where:
- (i) 1 mg mirdametinib dispersible tablet is dissolved/disintegrated in potable liquid to form solution
- (ii) administer the solution.
Practical scope:
This can support enforcement against specific pediatric formulation and administration workflow even when mg strength matches but dosage form differs.
Claims 24-25: osseous lesion subtypes
- Claim 24: distinctive bony lesion is:
- dysplasia of sphenoid bone, or
- dysplasia or thinning of long bone cortex
- Claim 25: distinctive osseous lesion is:
- sphenoid dysplasia, anterolateral bowing of tibia, or pseudarthrosis of long bone
Coverage logic:
These depend on the osseous lesion language embedded in Claim 10/12 criterion sets and narrow to defined NF1 bone manifestations.
Scope boundaries and “design-around” opportunities (based on claim text)
Most restrictive built-in constraints
- Treatment-naïve to MEK inhibitors (Claim 1 and repeated in Claims 14-15 and 23 as provided).
- Age 2 to 15 (all claims in the set as provided).
- Regimen-specific embodiments:
- BSA dosing table (Claim 13)
- 3-weeks-on/1-week-off cycle (Claim 15)
- maximum dosing structure (Claim 14)
- Method-outcome tie-ins:
- ≥20% volumetric reduction (Claim 16)
- response rate ≥70% selection logic (Claims 22)
- Formulation/workflow:
- dispersible 1 mg tablet dissolved in potable liquid, administered as solution (Claim 23)
Where competitors can narrow exposure
- If a competitor targets:
- patients with prior MEK inhibitor exposure, it can reduce risk against Claim 1’s key premise.
- a different dosing schedule (not 3-weeks-on/1-week-off), risk reduces for Claim 15.
- non-dispersible or different pediatric formulation steps, risk reduces for Claim 23.
- different clinical response definitions (not MRI volumetric centrally read with ≥20% reduction, or not selection logic ≥70%), risk reduces for Claims 16 and 21-22.
These are claim-structured levers, not clinical statements.
Patent landscape positioning: how this patent fits typical NF1/MEK inhibitor strategy
What this patent is best understood to claim
US 12,295,925 is a method-of-treatment and clinical protocol patent, not a composition patent, because:
- it requires a specific patient population (pediatric NF1 inoperable PN)
- it requires a specific drug (mirdametinib) administered orally
- it requires treatment constraints (no prior MEK inhibitor exposure)
- it requires administration and/or measurement workflows (BSA dosing table, cycle schedule, imaging thresholds, dosage reduction algorithm, objective response selection logic, dispersible tablet dissolution workflow)
Most likely overlap areas with other patents
Even without running an exhaustive claims-to-family search, the internal structure indicates likely overlap with:
- dosing regimen and pediatric administration protocol patents (BSA titration, cycle interruptions)
- imaging endpoint and responder-definition patents (volumetric MRI, centrally read response thresholds)
- patient selection criteria patents (NIH diagnostic criteria, molecular confirmation triggers)
- toxicity-management patents (acneiform-driven dose reduction algorithms)
- formulation patents (pediatric dispersible tablets and solution preparation workflow)
Key competitive enforcement focus
The most enforceable, easiest-to-prove elements in practice usually include:
- dosing table (Claim 13)
- cycle schedule (Claim 15)
- no prior MEK inhibitor exposure condition (Claim 1 premise)
- maximum dosing structure (Claim 14)
- objective volumetric reduction threshold (Claim 16) and responder-definition logic (Claims 21-22)
- dosing form workflow (Claim 23)
Claim scope vs likely regulatory labeling alignment (business relevance)
US method claims in this pattern typically track label language used in:
- pediatric dosing schedules (BSA-based dosing tables)
- treatment administration instructions (cycle schedules)
- clinical trial inclusion/exclusion (MEK inhibitor treatment-naïve requirement)
- assessment endpoints (volumetric MRI response)
- adverse event management instructions (dose interruption/reduction guidance)
Where labeling mirrors the claim elements, enforcement leverage increases because prescribing and trial protocol documentation can satisfy each claim element with less reconstruction.
Key Takeaways
- US 12,295,925 is a pediatric NF1 inoperable PN mirdametinib method patent with the strongest gatekeeper element being “no prior MEK inhibitor exposure” plus age 2 to 15.
- The patent narrows coverage through protocol-like constraints: BSA-based initial dosing (Claim 13), 3-weeks-on/1-week-off (Claim 15), dose reduction algorithm keyed to acneiform (Claims 19-20), and specific formulation workflow using 1 mg dispersible tablets dissolved into potable liquid (Claim 23).
- The patent ties method validity to measurable outcomes and selection logic: ≥20% MRI volumetric reduction (Claim 16) and selection based on objective response rate thresholds using centrally read MRI (Claims 21-22).
- For landscape and design-around strategy, the most potent claim-avoidance axes are prior MEK exposure, regimen schedule deviations, different pediatric administration workflow/formulation, and different imaging responder definitions.
FAQs
1) What is the central independent claim in this patent set?
Claim 1 is the core: it covers oral mirdametinib treatment of pediatric (2 to 15) NF1 patients with inoperable plexiform neurofibromas and no prior MEK inhibitor exposure.
2) Does the patent require that the PN be symptomatic or progressing?
Not for the base Claim 1, but Claims 2-5 add symptomatic/progressing/significant morbidity limitations.
3) How does the patent define pediatric dosing?
It provides a BSA-based twice-daily initial dosing table (Claim 13) and separately enforces a regimen maximum framing (Claim 14).
4) Is there a claimed treatment cycle schedule?
Yes. Claim 15 requires dosing for three weeks and discontinuation for one week in each four-week period.
5) Is a specific pediatric formulation and administration workflow claimed?
Yes. Claim 23 requires dissolving/disintegrating a 1 mg dispersible tablet in potable liquid to form a solution for twice-daily administration.
References
[1] U.S. Patent No. 12,295,925 (as provided in the prompt: claim text).
